JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Kodu・Aktsiate loetelu・Sana Biotechnology Inc

Sana Biotechnology Inc

Suletud

SektorTervishoid

3.27 -0.91

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.27

Max

3.31

Põhinäitajad
By Trading Economics
Sissetulek	-17M -59M
Töötajad	142
EBITDA	-19M -58M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+145.87% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-225M 880M
Eelmine avamishind	4.18
Eelmine sulgemishind	3.27

Uudiste sentiment

By Acuity

50%

160 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

1.68 / 1.87 Toetus ja vastupanu

Sana Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. mai 2026, 21:36 UTC

Omandamised, ülevõtmised, äriostud

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1. mai 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1. mai 2026, 18:37 UTC

Suurimad hinnamuutused turgudel

Senseonic Shares Slide on Underwritten Offering Price

1. mai 2026, 16:46 UTC

Suurimad hinnamuutused turgudel

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2. mai 2026, 19:57 UTC

Omandamised, ülevõtmised, äriostud

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2. mai 2026, 15:24 UTC

Tulu

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2. mai 2026, 12:46 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2. mai 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. mai 2026, 20:42 UTC

Tulu

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1. mai 2026, 19:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. mai 2026, 19:33 UTC

Market Talk

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1. mai 2026, 19:18 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1. mai 2026, 19:13 UTC

Market Talk

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1. mai 2026, 18:36 UTC

Tulu

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1. mai 2026, 18:35 UTC

Tulu

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1. mai 2026, 18:28 UTC

Tulu

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1. mai 2026, 18:27 UTC

Market Talk

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1. mai 2026, 18:14 UTC

Omandamised, ülevõtmised, äriostud

Barclays Completes Acquisition of Best Egg

1. mai 2026, 18:04 UTC

Tulu

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1. mai 2026, 17:43 UTC

Market Talk

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1. mai 2026, 17:37 UTC

Market Talk

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1. mai 2026, 17:30 UTC

Market Talk

Tulu

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1. mai 2026, 17:28 UTC

Market Talk

Tulu

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1. mai 2026, 17:21 UTC

Market Talk

Tulu

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1. mai 2026, 17:19 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1. mai 2026, 16:38 UTC

Market Talk

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1. mai 2026, 16:23 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Sana Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

145.87% tõus

12 kuu keskmine prognoos

Keskmine 8.04 USD 145.87%

Kõrge 12 USD

Madal 3.21 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Sana Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Sana Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.68 / 1.87Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

160 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.